SHPH - שווי פעילות לרווח לפני ריבית, מסים ופחת shuttlepharma.com

Shuttle Pharmaceuticals (SHPH) focuses on optimizing radiotherapy, where the primary growth drivers are Ropidoxuridine tests and the attainment of orphan drug status. The business relies on exclusive patents, which eliminates price wars due to the absence of approved analogs. This chart of share prices demonstrates an EV/EBITDA of 0.00, while the main risk for the company stems solely from potential scientific breakthroughs in R&D.

The investment attractiveness of Shuttle Pharmaceuticals (SHPH) is determined by the ratio of the business's market value to its earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple of a capital-intensive business, an investor assesses the payback period of assets inclusive of net debt, which is critical for capital-heavy industries. For Shuttle Pharmaceuticals, this metric confirms the effectiveness of strict cost controls during the development of radiation therapy.